News and Trends 28 Sep 2022 Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors (XE) based on foundations such as the CasX enzyme will enable genetic modification of natural killer (NK) cell therapies for cancer and will support Sanofi’s […] September 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Scope Biosciences and WUR to improve CRISPR-Cas technology with new funds Wageningen University & Research (WUR), and its spinoff Scope Biosciences, have received a grant of €150,000 ($152,000) from the European Research Council (ERC). The grant is to further research and enhance the diagnostic technology ScopeDx. This is based on CRISPR-Cas technology. Uniquely, this technology is able to quickly and accurately recognize viral or bacterial RNA. […] September 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September 8) they have a new structure to their 2018 strategic alliance in the CRISPR/Cas9 field. In 2018, science and technology company Merck, of which Sigma-Aldrich is a subsidiary, announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based […] September 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics This week it’s another four interview podcast, and the introduction of a new feature. Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO […] August 26, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Gene therapies for lung cancer identified by international team of scientists Gene therapies for lung cancer can be found by CRISPR genome editing technology, an international team of scientists have discovered. CRISPR genome-editing is a powerful tool that gives scientists a cheap and easy way to find and alter a specific piece of DNA within a cell – the ‘cut and paste’ of the biological world. […] August 24, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instability CRISPR/Cas9 is a commonly used gene editing technique. CRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types […] August 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Deciphering the molecular mechanisms of severe COVID-19 Researchers from Fujita Health University School of Medicine in Japan have been investigating COVID-19 to lead to therapeutic options against the severe form of the condition. Levels of proinflammatory cytokines are dramatically elevated in severe COVID-19 patients, the molecular mechanisms of which remain unclear. In a recent article in mBio, the researchers elucidated the role […] August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 SNIPR Biome announces new patent granted for applications targeting E. coli infections SNIPR Biome has today (August 2) announced that it has been granted a patent for medical applications supporting the company’s lead program – a bacteriophage cocktail targeting E.coli infections. Granted by the US Patent and Trademark Office (USPTO), the patent adds to its intellectual property portfolio that contains more than 20 granted patents in the […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Opinion 16 May 2022 CRISPR Can Help The Switch To Sustainable Cosmetics The cosmetics industry is looking for greener ingredients as consumers demand more sustainable products. According to Jon Kratochvil at ERS Genomics, which licenses out patents belonging to the gene editing pioneers Emmanuelle Charpentier and Jennifer Doudna, CRISPR-Cas9 could one day meet the demand for alternatives. The global cosmetics industry is worth more than €480B ($500B), […] May 16, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2021 UK Startup Lands €5M Seed Round to Produce Gene-Edited Crops with AI Phytoform, a London- and Boston-based startup, has received a €5M ($5.7M) investment to develop gene-edited crops with the help of artificial intelligence tools. The firm expects to bring its first product, a weather-resistant tomato, to market in early 2022. The seed financing will fuel the development of Phytoform’s precision crop breeding platform, which specializes in […] December 17, 2021 - 4 minutesmins - By Dan Samorodnitsky Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2021 Gene-Edited T Cell Therapy Players Battle Safety Doubts Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused all clinical development following the detection of an unexpected genetic change in a clinical trial. Industry experts see these events as a reality check for the nascent field. Off-the-shelf treatments that use genetically engineered T cells to treat diseases suffered […] October 22, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 4 May 2021 Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe Last month, the US firm bluebird bio abandoned the sale of its gene therapy Zynteglo in Germany after a pricing dispute with health authorities — a blow that could have repercussions for the rollout of other gene therapies in Europe. Zynteglo was approved in the EU in 2019 as the first-ever gene therapy for the […] May 4, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email